产品
编 号：F033555
分子式：C14H15Cl2NO3
分子量：316.18
分子式：C14H15Cl2NO3
分子量：316.18
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1093757-42-6
产品详情
生物活性：
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD).
体内研究：
VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats.VU0155041 (93 nnmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480)-induced akinesia in rats.Animal Model:Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g)
Dosage:31 nmol, 93 nmol (10 μL)
Administration:Intracerebroventrical injection, after the Haloperidol (1.5 mg/kg) treatment 2 hours
Result:Decreased the cataleptic effects of Haloperidol, and the effects still presented 30 min after infusion.
体外研究：
VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons.
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD).
体内研究：
VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy induced by the dopamine D2 receptor antagonist Haloperidol (1.5 mg/kg, i.p.) in rats.VU0155041 (93 nnmol, 316 nmol; i.c.v.) reverses Reserpine (HY-N0480)-induced akinesia in rats.Animal Model:Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g)
Dosage:31 nmol, 93 nmol (10 μL)
Administration:Intracerebroventrical injection, after the Haloperidol (1.5 mg/kg) treatment 2 hours
Result:Decreased the cataleptic effects of Haloperidol, and the effects still presented 30 min after infusion.
体外研究：
VU0155041 (10 μM) does not affect NMDA receptor currents in striatal medium spiny neurons.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备